Natural production and functional effects of alternatively spliced interleukin-4 protein in asthma. 2012

Irina G Luzina, and Virginia Lockatell, and Sachin Lavania, and Edward M Pickering, and Phillip H Kang, and Yulia N Bashkatova, and Sergey M Andreev, and Sergei P Atamas
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

We have previously described an alternatively spliced isoform of IL-4 mRNA that omits exon 2 and is termed IL-4δ2. However, the natural production of IL-4δ2 protein and its association with disease have not been previously assessed due to unavailability of an antibody that interacts with IL-4δ2 without cross-reactivity with full length IL-4. We used a unique monoclonal antibody (mAb) that reacts with IL-4δ2, but not with IL-4, and observed that IL-4δ2 is naturally produced by T cells from patients with asthma, but not from healthy controls. The kinetics of IL-4δ2 and IL-4 production by phorbol myristate acetate (PMA)/ionomycin-activated cells differed, with IL-4δ2 increasing at 48-72h and IL-4 peaking at 24h. The steady-state levels of IL-4δ2 mRNA varied significantly among the donors and were discordant with the corresponding protein levels, suggesting post-transcriptional regulation of protein production. Polarized Th1 or Th2 lymphocytes were not a major source of IL-4δ2. Stimulation of cultured T lymphocytes with IL-4δ2 caused elevated production of IFN-γ, IL-10, IL-6, MCP-1, and TNF-α, with notable differences between patients and controls in the production of IFN-γ, IL-10, and IL-6. Thus, IL-4δ2 is natively produced not only as mRNA but also as a protein by cells other than Th1 or Th2. It is regulated post-transcriptionally, is associated with allergic asthma, and regulates production of other cytokines by primary T lymphocytes. Alternatively spliced interleukin-4 may be a new biomarker, a pathophysiological player, and possibly a molecular target for future therapies in asthma.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D015847 Interleukin-4 A soluble factor produced by activated T-LYMPHOCYTES that induces the expression of MHC CLASS II GENES and FC RECEPTORS on B-LYMPHOCYTES and causes their proliferation and differentiation. It also acts on T-lymphocytes, MAST CELLS, and several other hematopoietic lineage cells. B-Cell Growth Factor-I,B-Cell Stimulatory Factor-1,Binetrakin,IL-4,Mast Cell Growth Factor-2,B Cell Stimulatory Factor-1,B-Cell Growth Factor-1,B-Cell Proliferating Factor,B-Cell Stimulating Factor-1,B-Cell Stimulatory Factor 1,BCGF-1,BSF-1,IL4,MCGF-2,B Cell Growth Factor 1,B Cell Growth Factor I,B Cell Proliferating Factor,B Cell Stimulating Factor 1,B Cell Stimulatory Factor 1,Interleukin 4,Mast Cell Growth Factor 2
D017398 Alternative Splicing A process whereby multiple RNA transcripts are generated from a single gene. Alternative splicing involves the splicing together of other possible sets of EXONS during the processing of some, but not all, transcripts of the gene. Thus a particular exon may be connected to any one of several alternative exons to form a mature RNA. The alternative forms of mature MESSENGER RNA produce PROTEIN ISOFORMS in which one part of the isoforms is common while the other parts are different. RNA Splicing, Alternative,Splicing, Alternative,Alternate Splicing,Nested Transcripts,Alternate Splicings,Alternative RNA Splicing,Alternative RNA Splicings,Alternative Splicings,Nested Transcript,RNA Splicings, Alternative,Splicing, Alternate,Splicing, Alternative RNA,Splicings, Alternate,Splicings, Alternative,Splicings, Alternative RNA,Transcript, Nested,Transcripts, Nested

Related Publications

Irina G Luzina, and Virginia Lockatell, and Sachin Lavania, and Edward M Pickering, and Phillip H Kang, and Yulia N Bashkatova, and Sergey M Andreev, and Sergei P Atamas
September 2001, American journal of respiratory and critical care medicine,
Irina G Luzina, and Virginia Lockatell, and Sachin Lavania, and Edward M Pickering, and Phillip H Kang, and Yulia N Bashkatova, and Sergey M Andreev, and Sergei P Atamas
January 1995, Immunogenetics,
Irina G Luzina, and Virginia Lockatell, and Sachin Lavania, and Edward M Pickering, and Phillip H Kang, and Yulia N Bashkatova, and Sergey M Andreev, and Sergei P Atamas
March 2008, Molecular immunology,
Irina G Luzina, and Virginia Lockatell, and Sachin Lavania, and Edward M Pickering, and Phillip H Kang, and Yulia N Bashkatova, and Sergey M Andreev, and Sergei P Atamas
March 2004, Genes and immunity,
Irina G Luzina, and Virginia Lockatell, and Sachin Lavania, and Edward M Pickering, and Phillip H Kang, and Yulia N Bashkatova, and Sergey M Andreev, and Sergei P Atamas
November 1994, Biochimica et biophysica acta,
Irina G Luzina, and Virginia Lockatell, and Sachin Lavania, and Edward M Pickering, and Phillip H Kang, and Yulia N Bashkatova, and Sergey M Andreev, and Sergei P Atamas
December 1998, The American journal of physiology,
Irina G Luzina, and Virginia Lockatell, and Sachin Lavania, and Edward M Pickering, and Phillip H Kang, and Yulia N Bashkatova, and Sergey M Andreev, and Sergei P Atamas
September 1988, The EMBO journal,
Irina G Luzina, and Virginia Lockatell, and Sachin Lavania, and Edward M Pickering, and Phillip H Kang, and Yulia N Bashkatova, and Sergey M Andreev, and Sergei P Atamas
October 1992, Transplantation proceedings,
Irina G Luzina, and Virginia Lockatell, and Sachin Lavania, and Edward M Pickering, and Phillip H Kang, and Yulia N Bashkatova, and Sergey M Andreev, and Sergei P Atamas
June 2011, Frontiers in bioscience (Scholar edition),
Irina G Luzina, and Virginia Lockatell, and Sachin Lavania, and Edward M Pickering, and Phillip H Kang, and Yulia N Bashkatova, and Sergey M Andreev, and Sergei P Atamas
October 1999, Tissue antigens,
Copied contents to your clipboard!